Global Pregabalin Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: July 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Pregabalin Market was valued at $1.9 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 4.5% CAGR, to an estimated market size of $2.3 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global pregabalin market encompasses the production and distribution of pregabalin, a gabapentinoid medication acting as an anticonvulsant and anxiolytic. It is primarily indicated for the treatment of neuropathic pain, fibromyalgia, epilepsy (as adjunctive therapy), and generalized anxiety disorder (GAD). The scope includes branded pharmaceuticals, generic formulations, and various dosage forms such as immediate-release capsules, oral solutions, and extended-release tablets.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Pregabalin Market in the period 2025-30:
- The aging global population is significantly increasing the prevalence of age-related conditions like fibromyalgia and post-herpetic neuralgia.
- There is a major clinical shift toward non-opioid pain management strategies, positioning pregabalin as a preferred alternative for chronic pain in North America.
- Widespread patent expirations of branded drugs have catalyzed generic competition, drastically reducing prices while expanding patient access in emerging markets.
- Advancements in extended-release (ER) drug delivery technologies are improving patient compliance and driving a shift away from immediate-release formulations.
- The integration of Artificial Intelligence (AI) is optimizing pharmacovigilance and drug discovery to identify novel indications and monitor adverse events.
- Rising global rates of diabetes are fueling a surge in diabetic peripheral neuropathy, which remains the largest application segment for the drug.
- Increased mental health awareness and destigmatization are leading to higher prescription volumes for generalized anxiety disorder.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Neuropathic Pain
- Anxiety Disorders
- Epilepsy